SUVOREXANT TAB,ORAL
Clinical Criteria Summary
Exclusion Criteria
- Narcolepsy and/or cataplexy (familial or idiopathic)
- Concomitant therapy with strong CYP3A4 inhibitors
- Circadian rhythm sleep disorders, restless legs syndrome, parasomnia including nightmare disorder, sleep terror disorder, sleepwalking disorder, or REM behavior disorder
- Active substance use disorder
- Considered a high suicide risk
- Untreated sleep-related breathing disorder-obstructive or central sleep apnea syndrome or central alveolar hypoventilation syndrome
- Severe hepatic impairment (i.e., Child-Pugh C)
- Concurrent use with any other sedative hypnotics for the treatment of insomnia
Inclusion Criteria
- Prescribed and monitored by a VA/VA Community Care sleep specialist or locally designated expert in sleep disorders
- Documented diagnosis of insomnia characterized by difficulties with sleep onset and/or sleep maintenance
- When available, cognitive behavioral therapy for insomnia (CBT-I) has been tried, via face to face, tele-mental health or non-VA care
- An adequate short-term trial of 2 formulary sedative hypnotics for the treatment of sleep onset and maintenance have been tried and failed to resolve symptoms or were not tolerated
- An adequate trial of daridorexant has been tried and failed or was not tolerated